marked.bio

RAS(ON) multi-selective inhibitor · small molecule

daraxonrasib

13 active trials across 2 of our biomarkers, targeting RAS (multi-selective). Not approved for any biomarker on marked.bio yet.

Also known as RMC-6236, Rasonque.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12D 12 12 Phase 3
KRAS G12C 11 11 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of daraxonrasib.

  1. Revolution Medicines 9
  2. Tango Therapeutics 1
  3. Amgen 1

Trials

13 of 13 trials shown

  1. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2029-03 NCT07805954

    daraxonrasibgemcitabinenab-paclitaxelzoldonrasib

    …ib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    KRAS G12DPancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

  2. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    Recruiting Phase 3 Revolution Medicines Started 2025Primary completion 2027-12 NCT06881784

    daraxonrasibdocetaxel

    Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).

    KRAS G12CKRAS G12DNSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

  3. Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

    Active, not recruiting Phase 3 Revolution Medicines Started 2024Primary completion 2026-06 NCT06625320

    daraxonrasibgemcitabinenab-paclitaxelirinotecanliposomal irinotecanfluorouracilleucovorinoxaliplatin

    RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, …

    KRAS G12CKRAS G12DPancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

  4. Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations

    Not yet recruiting Phase 1/2 Children's Oncology Group Starts 2027Primary completion 2032-04 NCT07819838

    daraxonrasib

    PARTS A1 AND A2: Patients with relapsed or refractory RAS mutant extracranial solid tumors

    KRAS G12CKRAS G12DRecurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm

  5. Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

    Not yet recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2026Primary completion 2030-11 NCT07793253

    daraxonrasib

    Documented KRAS mutation

    KRAS G12CKRAS G12DBiliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma

  6. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2026Primary completion 2029-05 NCT07397338

    daraxonrasibelironrasibzoldonrasibivonescimabcarboplatincisplatinpemetrexedcetuximab

    …ogically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.

    KRAS G12CKRAS G12DAdvanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC

  7. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    Recruiting Phase 1/2 Tango Therapeutics Started 2025Primary completion 2027-06 NCT06922591

    TNG462zoldonrasibdaraxonrasibmFOLFIRINOXgemcitabinenab-paclitaxel

    Arms A and B only: Has a tumor with a RAS mutation

    KRAS G12CKRAS G12DPDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation

  8. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2027-06 NCT06162221

    elironrasibdaraxonrasibpembrolizumabcisplatincarboplatinpemetrexedzoldonrasib

    Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)

    KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

  9. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2028-09 NCT06445062

    daraxonrasibmFOLFOX6bevacizumabmFOLFIRINOXcetuximabgemcitabinenab-paclitaxelzoldonrasibFOLFIRI

    …reatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unre…

    KRAS G12CKRAS G12DColorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC

  10. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2023Primary completion 2028-12 NCT06128551

    elironrasibdaraxonrasib

    Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy

    KRAS G12CNon-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

  11. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Recruiting Phase 1/2 Revolution Medicines Started 2022Primary completion 2027-05 NCT05379985

    daraxonrasib

    …ally confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing.

    KRAS G12CKRAS G12DNon-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

  12. A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

    Active, not recruiting Phase 1 Amgen Started 2024Primary completion 2026-10 NCT06360354

    Anvumetostatgemcitabinenab-paclitaxelFOLFIRINOXdaraxonrasib

    Rat Sarcoma Viral Oncogene Homolog (RAS) mutation

    KRAS G12CKRAS G12DAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

  13. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    Recruiting Phase 1 Revolution Medicines Started 2023Primary completion 2026-12 NCT06040541

    zoldonrasibdaraxonrasib

    Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation

    KRAS G12DNon-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors